Clinical Trials

Find a Trial

Trial Summary

Protocol No.GU115/I6A-MC-CBBD
Principal InvestigatorAlbany, Costantine
PhasePhase II
Age GroupAdult
TitleA Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men with Metastatic Castration Resistant Prostate Cancer
DescriptionThe main purpose of this study is to evaluate the safety and effectiveness of the study drug known as LY3023414 in combination with enzalutamide in men with prostate cancer.
Key EligibilityIn order to be eligible to take part in this trial, patients must meet the following criteria:

  • Males 18 years old or older
  • Confirmed adenocarcinoma of the prostate.
For a full list of participation criteria, please visit
Applicable Disease SitesProstate Cancer
Participating InstitutionsIndiana University (IU)
  • Eskenazi Hospital
  • Indiana University Hospital / IU Simon Cancer Center
Treatment TypeTreatment
ContactPhone: (317) 278-5632